Considering the pro-inflammatory role of this cytokine in some specific pathological contexts, inhibiting/down-regulating IL-6-mediated pathways could offer promising benefits for patients, and that is why IL-6-targeted therapies have been developed over the last few years and appear as interesting options in several immune-related diseases or even in cancers [13]. The gene discussed is IL6; the disease is cancer.